760 related articles for article (PubMed ID: 26853180)
1. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
[TBL] [Abstract][Full Text] [Related]
2. Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Singh S; Kalb RE; de Jong EMGJ; Shear NH; Lebwohl M; Langholff W; Hopkins L; Srivastava B; Armstrong AW
Am J Clin Dermatol; 2018 Dec; 19(6):879-886. PubMed ID: 30267377
[TBL] [Abstract][Full Text] [Related]
3. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Warren RB; Smith CH; Yiu ZZN; Ashcroft DM; Barker JNWN; Burden AD; Lunt M; McElhone K; Ormerod AD; Owen CM; Reynolds NJ; Griffiths CEM
J Invest Dermatol; 2015 Nov; 135(11):2632-2640. PubMed ID: 26053050
[TBL] [Abstract][Full Text] [Related]
4. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice.
Vilarrasa E; Notario J; Bordas X; López-Ferrer A; Gich IJ; Puig L
J Am Acad Dermatol; 2016 Jun; 74(6):1066-72. PubMed ID: 27004803
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.
Zweegers J; Groenewoud JMM; van den Reek JMPA; Otero ME; van de Kerkhof PCM; Driessen RJB; van Lümig PPM; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Arnold WP; Andriessen MPM; Kuijpers ALA; Berends MAM; Kievit W; de Jong EMGJ
Br J Dermatol; 2017 Apr; 176(4):1001-1009. PubMed ID: 27579864
[TBL] [Abstract][Full Text] [Related]
6. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
[TBL] [Abstract][Full Text] [Related]
7. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Menter A; Papp KA; Gooderham M; Pariser DM; Augustin M; Kerdel FA; Fakharzadeh S; Goyal K; Calabro S; Langholff W; Chavers S; Naessens D; Sermon J; Krueger GG
J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1148-58. PubMed ID: 27027388
[TBL] [Abstract][Full Text] [Related]
8. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Ossenkoppele PM; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
Br J Dermatol; 2016 Aug; 175(2):340-7. PubMed ID: 26989852
[TBL] [Abstract][Full Text] [Related]
9. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial.
Atalay S; van den Reek JMPA; den Broeder AA; van Vugt LJ; Otero ME; Njoo MD; Mommers JM; Ossenkoppele PM; Koetsier MI; Berends MA; van de Kerkhof PCM; Groenewoud HMM; Kievit W; de Jong EMGJ
JAMA Dermatol; 2020 Apr; 156(4):393-400. PubMed ID: 32049319
[TBL] [Abstract][Full Text] [Related]
11. Biologic drug survival in Israeli psoriasis patients.
Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
[TBL] [Abstract][Full Text] [Related]
12. Improved effectiveness from individualized dosing of self-administered biologics for the treatment of moderate-to-severe psoriasis: a 5-year retrospective chart review from a Spanish University Hospital.
Sanz-Gil R; Pellicer A; Montesinos MC; Valcuende-Cavero F
J Dermatolog Treat; 2020 Jun; 31(4):370-377. PubMed ID: 30924390
[No Abstract] [Full Text] [Related]
13. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry.
Fiorentino D; Ho V; Lebwohl MG; Leite L; Hopkins L; Galindo C; Goyal K; Langholff W; Fakharzadeh S; Srivastava B; Langley RG
J Am Acad Dermatol; 2017 Nov; 77(5):845-854.e5. PubMed ID: 28893407
[TBL] [Abstract][Full Text] [Related]
14. Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis.
Feldman SR; Zhao Y; Zhou H; Herrera V; Tian H; Li Y
J Manag Care Spec Pharm; 2017 May; 23(5):583-589. PubMed ID: 28448778
[TBL] [Abstract][Full Text] [Related]
15. Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics.
Ritchlin CT; Stahle M; Poulin Y; Bagel J; Chakravarty SD; Kafka S; Srivastava B; Langholff W; Gottlieb AB
BMC Rheumatol; 2019; 3():52. PubMed ID: 31799498
[TBL] [Abstract][Full Text] [Related]
16. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
Feldman SR; Zhao Y; Navaratnam P; Friedman HS; Lu J; Tran MH
J Manag Care Spec Pharm; 2015 Mar; 21(3):201-9. PubMed ID: 25726029
[TBL] [Abstract][Full Text] [Related]
17. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria.
Richter L; Vujic I; Sesti A; Monshi B; Sanlorenzo M; Posch C; Rappersberger K
J Dtsch Dermatol Ges; 2017 Mar; 15(3):309-317. PubMed ID: 28240404
[TBL] [Abstract][Full Text] [Related]
18. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Papp K; Gottlieb AB; Naldi L; Pariser D; Ho V; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Krueger G
J Drugs Dermatol; 2015 Jul; 14(7):706-14. PubMed ID: 26151787
[TBL] [Abstract][Full Text] [Related]
19. Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility Study.
van Bezooijen JS; van Doorn MBA; Schreurs MWJ; Koch BCP; Te Velthuis H; Prens EP; van Gelder T
Ther Drug Monit; 2017 Aug; 39(4):379-386. PubMed ID: 28570371
[TBL] [Abstract][Full Text] [Related]
20. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
Ross C; Marshman G; Grillo M; Stanford T
Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
